11/5/2026

speaker
Conference Operator
Operator

Greetings and welcome to Rigel Pharmaceuticals' financial conference call for the third quarter, 2026. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you, Mr. Furey. You may begin.

speaker
Ray Furey
Executive Vice President, General Counsel, and Corporate Secretary

Thank you. Welcome to our third quarter 2026 financial results conference call. The financial press release for the third quarter 2026 was issued earlier today and can be viewed, along with the slides for this presentation, in the news and events section of our investor relations site on Rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for commercial regulatory product development and other business activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found on our most recent annual report on Form 10-K for the year ended December 31st, 2025, on file with the SEC, and subsequent filings with the SEC, including our Q3 quarterly report on Form 10Q with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances, except as required by law. At this time, I would like to turn the call over to our President

speaker
Raul Rodriguez
President and Chief Executive Officer

and Chief Executive Officer Raul Rodriguez. Raul? Thank you, Ray, and thank you all for joining us today. Also joining me on the call are Dave Santos, our Chief Commercial Officer, Dr. Alison Hannah, our Chief Medical Officer, and Dean Schorno, our Chief Financial Officer. Before we begin, I'd like to share a few key highlights from the quarter. We delivered over $72 million in net product sales, our highest ever, and another profitable quarter. This while making important, taking important steps towards Rigel's next phase of growth. Fepinu, Rigel's fourth commercial product, is now available in the U.S. with an encouraging start to its launch, and we continue to advance R289 towards its next stage of development. I'll start with an overview of this progress before the team takes you through the details. Moving to slide four. Webino became commercially available in the U.S. on August 13th and generated 6.6 million in net product sales through the end of the third quarter. Following the close of the Global In-License Agreement in June, our team moved quickly to initiate launch activities, leveraging our established commercial and medical infrastructure to engage physicians and build awareness ahead of commercial availability. Within just two months of closing the transaction, Vepinu was successfully integrated into our existing distribution network and ready for commercial launch. During Q3, we shipped Vepinu to over 100 patients and clinics. Encouragingly, the majority of the patients who received Vepinu during the early weeks of launch had already refilled their prescriptions by quarter end. We also have strong payer coverage with patients able to access Vepinu through either formulary coverage or through the exception process. In addition, we are seeing positive engagement with healthcare providers with our efforts focused on high docile prescribers. As the first and only FDA-approved ProTac therapy or prognosis targeting Chimera, Vepinu offers a new mechanism of action and an important treatment option for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Our focus now is on building awareness of its differentiated mechanism and clinical data, then translating this into adoption through multifaceted campaigns. Dave will share more about our early launch experience and plans shortly. Overall, we're excited by VetBeneu's early launch performance and believe it has the potential to be Rytel's largest sales contributor. On slide five, we outline our transformational growth strategy. The Bepinu launch is a clear example of this strategy in action. We identified a differentiated, late-stage asset in oncology and leveraged our established infrastructure to rapidly integrate and launch the product. We intend to build on that approach as we continue to grow our portfolio for commercial products and evaluate additional in-license opportunities. At the same time, we are investing in our development pipeline, led by R289, our dual IRAC 1 and 4 inhibitor, which is currently being evaluated in a Phase 1B clinical studies in patients with low and risk MDS. We look forward to presenting updated data on this study at the ASH meeting in December. Financial discipline is what connects these strategic objectives. Our growing commercial business enables us to invest in opportunities with substantial long-term potential We believe this combination of commercial execution, pipeline advancement, and financial discipline sets us apart and positions Rigel well for its next phase of growth. Slide 6 highlights our track record of commercial growth, and more importantly, the opportunities ahead for Rigel. We grew our net product sales by a compound annual growth rate of approximately 35% annually since 2022. Looking into the future, we have two sequential engines of significant growth, Vepinu and then R289. We are encouraged by Vepinu's early performance and see significant potential in a large and growing market. Turning to R289, we continue to advance its development in patients with lower risk MDS. A disease with significant unmet medical need. At the ASH meeting in December, we plan to present updated data from the Phase 1b study, including preliminary efficacy data from the dose expansion phase. We also remain on track to complete enrollment and select the recommended Phase 2 dose for future development by the end of 2026. We plan to initiate a registrational program in lower-risk MDS next year and believe that R289 has the potential to be a billion-dollar-plus commercial opportunity in this syndication. Together, Vepinu and R289 offer significant commercial potential, and they are central to our plans to substantially expand Rigel's business over the coming years and drive long-term shareholder value. With that, I'll turn the call over to Dave to discuss our commercial performance and the latest on the Vepinu launch. Dave?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation